CSPC Pharmaceutical Group Management
Management criteria checks 1/4
CSPC Pharmaceutical Group's CEO is Lei Cai, appointed in Dec 2025, has a tenure of less than a year. total yearly compensation is CN¥513.00K, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $40.82K. The average tenure of the management team and the board of directors is 1.1 years and 2.2 years respectively.
Key information
Lei Cai
Chief executive officer
CN¥513.0k
Total compensation
| CEO salary percentage | 9.94% |
| CEO tenure | less than a year |
| CEO ownership | 0.0003% |
| Management average tenure | 1.1yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | CN¥3b |
| Dec 31 2025 | CN¥513k | CN¥51k | CN¥4b |
Compensation vs Market: Lei's total compensation ($USD75.62K) is below average for companies of similar size in the US market ($USD14.46M).
Compensation vs Earnings: Insufficient data to compare Lei's compensation with company performance.
CEO
Lei Cai (46 yo)
Dr. Lei Cai was Non-Independent Director of CSPC Innovation Pharmaceutical Co. Ltd. from July 31, 2020 to December 22, 2025. Dr. Cai has Doctorate from National University of Singapore.Dr. Cai has Bachelo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 29.3yrs | CN¥14.27m | 26.39% $ 3.1b | |
| CEO & Vice Chairman of the Board | less than a year | CN¥513.00k | 0.00035% $ 40.8k | |
| COO & Vice-Chairman of the Board | less than a year | CN¥533.00k | 0.0026% $ 306.7k | |
| Executive Director & Chief Scientist | 8.6yrs | CN¥6.39m | 0.026% $ 3.1m | |
| Executive Director | no data | CN¥935.00k | 0.013% $ 1.5m | |
| Executive Director | no data | CN¥935.00k | 0.044% $ 5.1m | |
| Executive Director | 2.2yrs | CN¥5.45m | no data | |
| Executive Director | no data | CN¥918.00k | 0.00088% $ 102.6k | |
| Executive Director | 1.6yrs | CN¥1.30m | 0.00018% $ 21.0k | |
| Executive Director | less than a year | CN¥402.00k | no data | |
| Executive president & President of Global Research and Development | 1.8yrs | no data | no data | |
| Executive Director | less than a year | no data | no data |
Experienced Management: CSPC.Y's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 29.3yrs | CN¥14.27m | 26.39% $ 3.1b | |
| CEO & Vice Chairman of the Board | less than a year | CN¥513.00k | 0.00035% $ 40.8k | |
| COO & Vice-Chairman of the Board | less than a year | CN¥533.00k | 0.0026% $ 306.7k | |
| Executive Director & Chief Scientist | 8.6yrs | CN¥6.39m | 0.026% $ 3.1m | |
| Executive Director | 14.5yrs | CN¥935.00k | 0.013% $ 1.5m | |
| Executive Director | 8yrs | CN¥935.00k | 0.044% $ 5.1m | |
| Executive Director | 2.2yrs | CN¥5.45m | no data | |
| Executive Director | 2.2yrs | CN¥918.00k | 0.00088% $ 102.6k | |
| Executive Director | 1.6yrs | CN¥1.30m | 0.00018% $ 21.0k | |
| Executive Director | less than a year | CN¥402.00k | no data | |
| Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 5.5yrs | CN¥346.00k | no data |
Experienced Board: CSPC.Y's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 13:57 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CSPC Pharmaceutical Group Limited is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rebecca Liang | Bernstein |
| Ethan Cui | BofA Global Research |
| Yue-Kwong Lui | CGS International |